Hotspot Cancer Panels

Hotspot cancer panels target regions of known cancer genes that have been well-characterized as mutational hotspots. The small target region size produces a high depth of sequencing coverage per run, even when multiplexing many samples together. As a result, hotspot cancer panels provide a cost-effective and efficient method for discovering rare somatic mutations, many of which have been identified as important cancer drivers.

In addition to our proprietary OncoGxOne™ Discovery cancer panels, which assesses a number of specific tumor types, GENEWIZ also uses the TruSeq® Amplicon Cancer Panel from Illumina that targets 48 genes by amplicon sequencing on the Illumina MiSeq®, as well as the Ion AmpliSeq™ Cancer Hotspot Panel from Ion Torrent that targets 50 genes by amplicon sequencing on the Ion PGM™.

Request Quote
  Why Azenta   


Discover rare somatic mutations
Identify cancer mechanisms
Cancer biomarker discovery
Screen relevant cancer genes
Discover cancer biomarkers and therapeutic targets

Targeted Sequencing Features & Benefits

Targeted amplicon sequencing with extremely high depth and on-target coverage to discover rare somatic mutations

Screen many cancer genes in a single assay, and multiplex many samples in a single run, to maximize cost-effectiveness

Sequence difficult FFPE samples effectively

Compatibility with as little as 10 ng DNA input

Fast turnaround time

Hotspot Cancer Panel Workflow

Extensive Quality Control is Performed at the Conclusion of Each Step of the Process
  • Building

    Experimental Design

  • arrow
  • Target Amplification & Library Preparation

  • arrow
  • Building


  • arrow
  • Mutation Discovery


Technical Resources

Webinar| Non-Classical Sources of Tumour-Specific Antigen in Checkpoint Inhibitor Response

Developing immunotherapies for cancer can be difficult due to the variation of immune response from patient to patient. In this webinar, Dr. Litchfield from UCL Cancer Institute presents his team’s exploratory research using a multiomics approach to better understand the diversity of immune response to cancer and highlights their findings of an alternative source of a tumour-specific antigen in checkpoint inhibitor (CPI) response.


For information on our NGS platforms as well as recommended configurations of your projects, please visit the NGS Platforms page. Azenta does not guarantee data output or quality for sequencing-only projects.

10x Genomics

How To Order

Email | Phone 1-877-436-3949, Ext. 1